H
Huamao M. Lin
Researcher at Takeda Pharmaceutical Company
Publications - 2
Citations - 210
Huamao M. Lin is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Adverse effect & Hazard ratio. The author has an hindex of 1, co-authored 2 publications receiving 3 citations.
Papers
More filters
Journal ArticleDOI
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Caicun Zhou,Suresh S. Ramalingam,Tae Min Kim,Sang-We Kim,James Chih-Hsin Yang,Gregory J. Riely,Tarek Mekhail,Danny Nguyen,Maria Rosario Garcia Campelo,Enriqueta Felip,Sylvie Vincent,S. Jin,C. Griffin,Veronica Bunn,Jianchang Lin,Huamao M. Lin,M. Mehta,Pasi A. Jänne +17 more
TL;DR: In this paper, the authors evaluated treatment outcomes and safety of mobocertinib in patients with previously treated EGFRex20ins-positive mNSCLC, with a manageable safety profile.
Journal ArticleDOI
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D. Ross Camidge,Hye Ryun Kim,Myung-Ju Ahn,James Chih-Hsin Yang,Ji Youn Han,Maximilian Hochmair,Ki Hyeong Lee,Angelo Delmonte,Maria Rosario Garcia Campelo,Dong Wan Kim,Frank Griesinger,Enriqueta Felip,Raffaele Califano,Raffaele Califano,Alexander I. Spira,Scott N. Gettinger,Marcello Tiseo,Huamao M. Lin,Yuyin Liu,Florin Vranceanu,Huifeng Niu,Pingkuan Zhang,Sanjay Popat +22 more
TL;DR: In this article, the authors reported the final efficacy, safety, and exploratory results of the ALTA-1L trial, which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC.